SUMMARY Nine children with Duchenne muscular dystrophy were given Sanorex (mazindol), a growth hormone inhibitor, daily for 6 months. There was no significant change in their muscle function, but there was a significant reduction in weight gain and in levels of growth hormone, somatomedin C, hair zinc, serum zinc, and serum LDH. Selenium and glutathione peroxidase in the serum increased significantly. Thirteen other children with growth hormone deficiency had a significant reduction in hair selenium following growth hormone administration.
In a recent report of a family with Duchenne muscular dystrophy, an affected brother with growth hormone deficiency was substantially less disabled than his younger sibs.' Based on this observation, we decided to evaluate the effect of administering a growth hormone inhibitor to nine children with Duchenne muscular dystrophy.
Methods
The nine children studied had been followed for 1 to 9 years in our Muscular Dystrophy Clinic. Their diagnosis had been confirmed by the typical clinical course, characteristic physical findings, which included pelvifemoral weakness and calf pseudohypertrophy, family history, raised serum levels of creatinine kinase (CK), lactate dehydrogenase (LDH), and serum glutamate oxaloacetate transaminase (SGOT), and abnormal findings on muscle biopsy and electromyography. The ages of these nine children at the time of entry into the study were 5, 6, 7, 7, 8, 10, 12, 12 , and 14 years.
After a group discussion with all the parents, and individual discussions, a written informed consent *Supported in part by a grant from the Muscular Dystrophy Association, Nassau Chapter. Received for publication 21 October 1983. Accepted for publication 17 November 1983. was obtained for each child. The study was approved by our institutional research committee (IRB).
Each child received Sanorex 8 (mazindol) at a dose of 2 mg daily for 6 months. Careful manual muscle testing and peak flow during forced expiration were done for each child at the beginning of the study and at 3 and 6 months by one of us (JK), and accurate measurements of height and weight were done by at least two of us at each examination. Laboratory tests were also performed at the beginning of the study and at 3 and 6 months. Human growth hormone was assayed in serum obtained before and 90 minutes after the oral administration of clonidine (0 1 to 0 2 mg). Selenium was assayed in serum and hair by the fluorometric method.2 Glutathione peroxidase, CK, LDH, and SGOT were assayed by standard methods. Hair and serum zinc were assayed by atomic absorption spectrophotometry. Somatomedin C was assayed by radioimmunoassay. Parents were instructed in the method of collecting 24 hour urine specimens and creatinine was assayed in aliquots of these specimens.
Thirteen additional children (aged 2 to 16 years) with isolated growth hormone deficiency were studied. Six of them were given human growth hormone injections (two units three times a week Growth hormone inhibition causes increased selenium levels in Duchenne muscular dystrophy intramuscularly) and hair selenium was measured after 3 months of growth hormone therapy. These 13 children were 3 to 5 SD below the mean in height and had retarded bone ages. After insulin induced hypoglycaemia and intravenous arginine administration the peak serum growth hormone was below 5 ng/ml in all of them. The results of other trace element assays in these children will be reported separately.
Results
No significant change in muscle strength or peak expiratory flow was found in these nine children 12 tall girls who were emotionally disturbed by the fact that their predicted height was greater than 183 cm. Sanorex has been widely prescribed as an appetite suppressantl1 12 for obese patients and it did result in a reduction in the rate of weight gain in these children.
While selenium deficiency is known to cause white muscle disease in cattle, it has not been found to be deficient in children with muscular dystrophy. The levels in these children were all within the normal range we have reported for children on Long Island.2 However, it is interesting that a growth hormone inhibitor significantly increased both the serum selenium level and the glutathione peroxidase activity (a selenium dependent enzyme) in these children. Also, we have found that growth hormone administration to growth hormone deficient children lowered the hair selenium significantly. 
